A Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer

About this Study

The purpose of this study is to test whether Carvedilol (Coreg) can reduce the occurrence of heart problems during cancer treatment.

Sponsor Protocol ID:S1501
IRB Number:2018-0183
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study was designed to include women and minorities, but was not designed to measure differences of intervention effects

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Craft, Barbara S, M.D.
How to participate in our Clinical Trials